Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>BofAS Estimates ALI HEALTH (00241.HK) to Outrun Consensus in Current FY Results, Raises TP to $6.56
Recommend 38 Positive 55 Negative 17 |
||||
|
||||
|
BofA Securities' report predicted that ALI HEALTH (00241.HK) will beat consensus for its results in the current fiscal year ending March 2026. The broker raised its forecast for the company's current fiscal year revenue growth by 4 ppts to 14% and adjusted net profit growth forecast by 10 ppts to 30%. The broker also tuned up its adjusted net profit forecast for Alibaba Health for both the current and next fiscal year by 8%, and raised the expected FCF CAGR in FY2024-31 from 42% to 45%. The target price for Alibaba Health was increased from HK$5.5 to HK$6.56, with a reiterated Buy rating. The broker noted that key drivers for Alibaba Health's results beat include robust sales during the "618" event, accelerated investment by parent company BABA-W (09988.HK) in quick commerce boosting traffic on TTG, benefiting Alibaba Health with increased traffic from young users, B2C e-commerce cross-selling, and higher ad spending by merchants. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
